Heart device maker Edwards Lifesciences Corp. says it expects a sales boost from new and current products to drive double-digit earnings growth in 2010.
The company says it expects profit between $3.50 and $3.60 per share on revenue between $1.43 billion and $1.5 billion in 2010. The outlook represents up to 18 percent growth in earnings per share.
Analysts polled by Thomson Reuters expect $3.53 per share in profit on $1.42 billion in revenue in 2010.
The company says it expects to launch its new Sapien XT transcatheter valve in Europe during the first quarter. Meanwhile, it says recent product launches have been driving surgical valve sales and the momentum is expected to continue into 2010.
Latest from Today's Medical Developments
- GrindingHub Americas launches in 2027 in Cincinnati, Ohio
- Methods Machine Tools now offers the Nakamura-Tome NT-Flex
- Battelle awards $900,000 in STEM education grants to Ohio schools
- #55 Lunch + Learn Podcast with KINEXON
- Starrett and Gerstner offer limited edition, American made 1950s replica wooden machinist tool chests
- EMCO’s UNIVERSALTURN 50: The new benchmark in universal turning
- Archetype's Expertise for Equity accelerates early-stage innovation
- Stratasys expands its AM solutions with Tritone's cutting-edge technology
